Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies

Registration



Date:
Wednesday, August 11, 2021
Time: 1:00PM – 3:00PM HST
Location: Fairmont Orchid - 1 North Kaniku Drive, Kohala Coast, HI 96743 
                 Grande Ballroom

(Live stream opportunities will be available)

Symposium Overview
This live satellite symposium will take place at the 2021 Pan Pacific Lymphoma Conference and will be presented by three renowned experts actively engaged in the care of patients with lymphoma. This symposium will also be live-streamed for those who may not be able to attend in person.

Target Audience
This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives
After participating in the activity, participants should be better able to:

  • Discuss the rationale for using cellular-based therapies for patients with hematologic malignancies
  • Evaluate the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and myeloma
  • Assess practical approaches to the use of cellular therapy, including patient referral and adverse event management strategies

​​​
Continuing Education

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
The University of Nebraska Medical Center designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for up to 2.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

 

Content/Agenda

1:00 PM       Welcome, Introduction, and Pre-Session Survey
1:10 PM       Rationale for Cell Therapy in Patients with Lymphoma and Myeloma: Targeting CD19, BCMA, and Other Cellular Markers
1:25 PM       Review of the Latest Clinical Trial Data: Cell Therapy for Patients with Lymphoma
1:45 PM       Review of the Latest Clinical Trial Data: Cell Therapy for Patients with Multiple Myeloma
2:05 PM       Emerging Cell Therapies in Other Hematologic Malignancies
2:15 PM       Strategies for Bridging the Gap Between Academic and Community Practices: Referring Patients for Potentially Curative Therapy
2:30 PM       Expert Panel: Optimizing Safety of Cell Therapy in Patients with Hematologic Malignancies
2:45 PM       Audience Q&A
2:55 PM       Recap of Key Points and Post-Session Survey

3:00 PM       Adjorn

Chair
Julie Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center | Omaha, Nebraska

Faculty
Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco | San Francisco, California


Tara Graff, DO
Specializes in Hematology/Oncology
Mission Blood + Cancer | Des Moines, Iowa


Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC. 

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

Faculty
Julie Vose, MD, MBA
Morphosys (Self): Consultant (Status: Ongoing); AbbVie (Self): Consultant (Status: Ongoing); Pharmacyclics (Self): Consultant (Status: Ongoing); Astra-Zeneca (Self): Consultant (Status: Ongoing)

Nina Shah, MD
Glaxo Smith-Kline (Self): Consultant (Status: Ongoing); Amgen (Self): Consultant (Status: Ongoing); Indapta Therapeutics (Self): Consultant (Status: Ongoing);Sanofi (Self): Consultant (Status: Ongoing); CareDX (Self): Consultant (Status: Ongoing); Kite (Self): Consultant (Status: Ongoing);  Karyopharm (Self): Consultant (Status: Ongoing); Oncopeptides (Self): Consultant (Status: Ongoing); Celgene/Bristol Myers Squibb (Self): Research (Status: Ongoing); Janssen (Self): Research (Status: Ongoing); Bluebird Bio (Self): Research (Status: Ongoing); Sutro Biopharma (Self): Research (Status: Ongoing); Teneobio (Self): Research (Status: Ongoing); Poseida (Self): Research (Status: Ongoing); Nektar (Self): Research (Status: Ongoing)

Tara Graff, DO
Astra-Zeneca (Self): Consultant (Status: Ongoing); AbbVie (Self): Consultant (Status: Ongoing); TG Therapeutics (Self): Consultant (Status: Ongoing); Karyopharm (Self): Consultant (Status: Ongoing); BMS/Celgene (Self): Consultant (Status: Ongoing); Adaptive Biotech (Self): Consultant (Status: Ongoing)

Planning Committee
The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​; Valeta Creason-Wahl, HMCC; Renee Paulin, MSN, RN, CWOCN
Bio Ascend: Jennifer Bechan; Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by independent educational grants from Bristol Myers Squibb and Legend Biotech.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.